{"id":"salmeterol-sn408d","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nervousness"},{"rate":"1-3","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1263","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. Its long duration of action (12 hours) is due to its lipophilic properties, which allow it to partition into airway tissue and provide sustained receptor activation. It is typically used in combination with inhaled corticosteroids for maintenance therapy in asthma and COPD.","oneSentence":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:27.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy (in combination with inhaled corticosteroid)"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT00950794","phase":"PHASE4","title":"Study of Salmeterol (SN408D) for Adult Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Asthma, Bronchial Asthma","enrollment":367}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Salmeterol(SN408D)","genericName":"Salmeterol(SN408D)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy (in combination with inhaled corticosteroid), Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}